<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749981</url>
  </required_header>
  <id_info>
    <org_study_id>2012/631-632-633</org_study_id>
    <nct_id>NCT02749981</nct_id>
  </id_info>
  <brief_title>Cefazolin Dosing in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass</brief_title>
  <acronym>CEFA</acronym>
  <official_title>Cefazolin Dosing in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics of cefazolin in children undergoing cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the time during which the unbound cefazolin concentration is above the MIC of S. aureus (fT&gt;MIC) with the current dosing regimen</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimalisation of the cefazolin dosing regimen to aim for a target unbound cefazolin concentration above the MIC of S. aureus during surgery</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <description>patients receiving cefazolin as part of routine clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood and tissue sampling</intervention_name>
    <arm_group_label>Cefazolin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        children undergoing cardiac surgery with cardiopulmonary bypass
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pediatric patients undergoing cardiac surgery with cardiopulmonary bypass

          -  minimum weight 1.8 kg

          -  intra-arterial or intravenous access other than the drug infusion line available for
             blood sampling (arterial line is preferred)

        Exclusion Criteria:

          -  no catheter in place for blood sampling

          -  absence of parental/patient consent

          -  known hypersensitivity to cefazolin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrien Francois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital, Department of Cardiac Surgery</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

